With $5B in China sales, AstraZeneca doubles down on Chinese biopharma innovation

Amber Tong

Senior Editor

Ayisha Sharma

News Reporter

CAMBRIDGE, UK — AstraZeneca said it will continue to be the conduit for sharing Chinese innovation with the rest of the world, but will establish a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With $5B in China sales, AstraZeneca doubles down on Chinese biopharma innovation

Amber Tong

Senior Editor

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

Senior Editor

News Reporter

Sign up to read this article for free.

With $5B in China sales, AstraZeneca doubles down on Chinese biopharma innovation